Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression

Genna M. Luciani; Lihua Xie; David Dilworth; Anne Tierens; Yoni Moskovitz; Alex Murison; Magdalena M. Szewczyk; Amanda Mitchell; Mathieu Lupien; Liran Shlush; John E. Dick; Cheryl H. Arrowsmith; Dalia Barsyte-Lovejoy; Mark D. Minden

doi:10.1016/j.exphem.2018.10.006

Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression

Genna M. Luciani
, Lihua Xie
, David Dilworth
, Anne Tierens
, Yoni Moskovitz
, Alex Murison
, Magdalena M. Szewczyk
, Amanda Mitchell
, Mathieu Lupien
, Liran Shlush
, John E. Dick
, Cheryl H. Arrowsmith
, Dalia Barsyte-Lovejoy
, Mark D. Minden

University of Toronto
University Health Network
Toronto General Hospital
Weizmann Institute of Science

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and thus has among the worst long-term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and required for repopulation in vitro and in vivo. CD34 expression in OCI-AML-20 shows dependence on the co-culture with stromal cells. Transcriptome analysis indicates that the OCI-AML-20 clusters with other AML patient data sets that have poor prognosis, as well as other AML cell lines, including another inv(3) line, MUTZ-3. OCI-AML-20 is a new cell line resource for studying the biology of inv(3) AML that can be used to identify potential therapies for this poor outcome disease.

Original language	English
Pages (from-to)	27-36
Number of pages	10
Journal	Experimental Hematology
Volume	69
DOIs	https://doi.org/10.1016/j.exphem.2018.10.006
State	Published - Jan 2019
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2018

Funding

This work was supported by the Leukemia Lymphoma Society of Canada . The Structural Genomics Consortium is a registered charity (1097737) that receives funds from AbbVie; Bayer Pharma AG; Boehringer Ingelheim; Canada Foundation for Innovation; Eshelman Institute for Innovation; Genome Canada; Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD grant no. 115766 ); Janssen; Merck & Co.; Novartis Pharma AG; Ontario Ministry of Economic Development and Innovation; Pfizer; São Paulo Research Foundation-FAPESP; Takeda; and the Wellcome Trust.

Funders	Funder number
Bayer Pharma AG
EU/EFPIA	115766
Eshelman Institute for Innovation
Boehringer Ingelheim
Takeda Pharmaceutical Company
Genome Canada
Novartis Pharma
Leukemia and Lymphoma Society of Canada	1097737
Wellcome Trust
Innovative Medicines Canada
Pfizer Canada
Janssen Canada
Ontario Ministry of Economic Development and Innovation
Canada Foundation for Innovation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.exphem.2018.10.006

Cite this

Luciani, G. M., Xie, L., Dilworth, D., Tierens, A., Moskovitz, Y., Murison, A., Szewczyk, M. M., Mitchell, A., Lupien, M., Shlush, L., Dick, J. E., Arrowsmith, C. H., Barsyte-Lovejoy, D., & Minden, M. D. (2019). Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression. Experimental Hematology, 69, 27-36. https://doi.org/10.1016/j.exphem.2018.10.006

@article{4489898d837345b7b7f6538ef0a995c4,

title = "Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression",

abstract = "Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and thus has among the worst long-term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and required for repopulation in vitro and in vivo. CD34 expression in OCI-AML-20 shows dependence on the co-culture with stromal cells. Transcriptome analysis indicates that the OCI-AML-20 clusters with other AML patient data sets that have poor prognosis, as well as other AML cell lines, including another inv(3) line, MUTZ-3. OCI-AML-20 is a new cell line resource for studying the biology of inv(3) AML that can be used to identify potential therapies for this poor outcome disease.",

author = "Luciani, \{Genna M.\} and Lihua Xie and David Dilworth and Anne Tierens and Yoni Moskovitz and Alex Murison and Szewczyk, \{Magdalena M.\} and Amanda Mitchell and Mathieu Lupien and Liran Shlush and Dick, \{John E.\} and Arrowsmith, \{Cheryl H.\} and Dalia Barsyte-Lovejoy and Minden, \{Mark D.\}",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2019",

month = jan,

doi = "10.1016/j.exphem.2018.10.006",

language = "אנגלית",

volume = "69",

pages = "27--36",

journal = "Experimental Hematology",

issn = "0301-472X",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression

AU - Luciani, Genna M.

AU - Xie, Lihua

AU - Dilworth, David

AU - Tierens, Anne

AU - Moskovitz, Yoni

AU - Murison, Alex

AU - Szewczyk, Magdalena M.

AU - Mitchell, Amanda

AU - Lupien, Mathieu

AU - Shlush, Liran

AU - Dick, John E.

AU - Arrowsmith, Cheryl H.

AU - Barsyte-Lovejoy, Dalia

AU - Minden, Mark D.

PY - 2019/1

Y1 - 2019/1

N2 - Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and thus has among the worst long-term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and required for repopulation in vitro and in vivo. CD34 expression in OCI-AML-20 shows dependence on the co-culture with stromal cells. Transcriptome analysis indicates that the OCI-AML-20 clusters with other AML patient data sets that have poor prognosis, as well as other AML cell lines, including another inv(3) line, MUTZ-3. OCI-AML-20 is a new cell line resource for studying the biology of inv(3) AML that can be used to identify potential therapies for this poor outcome disease.

AB - Acute myeloid leukemia (AML) is a complex, heterogeneous disease with variable outcomes following curative intent chemotherapy. AML with inv(3) is a genetic subgroup characterized by a very low response rate to current induction type chemotherapy and thus has among the worst long-term survivorship of the AMLs. Here, we describe OCI-AML-20, a new AML cell line with inv(3) and deletion of chromosome 7; the latter is a common co-occurrence in inv(3) AML. In OCI-AML-20, CD34 expression is maintained and required for repopulation in vitro and in vivo. CD34 expression in OCI-AML-20 shows dependence on the co-culture with stromal cells. Transcriptome analysis indicates that the OCI-AML-20 clusters with other AML patient data sets that have poor prognosis, as well as other AML cell lines, including another inv(3) line, MUTZ-3. OCI-AML-20 is a new cell line resource for studying the biology of inv(3) AML that can be used to identify potential therapies for this poor outcome disease.

UR - https://www.scopus.com/pages/publications/85056170124

U2 - 10.1016/j.exphem.2018.10.006

DO - 10.1016/j.exphem.2018.10.006

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 30352278

AN - SCOPUS:85056170124

SN - 0301-472X

VL - 69

SP - 27

EP - 36

JO - Experimental Hematology

JF - Experimental Hematology

ER -

Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expression

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this